Targeted therapies: Using β-blockers to inhibit breast cancer progression
- PMID: 21808268
- DOI: 10.1038/nrclinonc.2011.123
Targeted therapies: Using β-blockers to inhibit breast cancer progression
Abstract
Three recent population studies have translated laboratory investigations into a clinical setting and concur in presenting evidence that suggest a dramatic new role for β-blockers in reducing metastases, tumor recurrence and specific mortality in breast cancer. Should we be skeptical about these controversial findings?
Comment on
-
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.J Clin Oncol. 2011 Jul 1;29(19):2645-52. doi: 10.1200/JCO.2010.33.4441. Epub 2011 May 31. J Clin Oncol. 2011. PMID: 21632501 Free PMC article.
-
Beta blockers and breast cancer mortality: a population- based study.J Clin Oncol. 2011 Jul 1;29(19):2635-44. doi: 10.1200/JCO.2010.33.5422. Epub 2011 May 31. J Clin Oncol. 2011. PMID: 21632503
Similar articles
-
The role of adrenergic signaling in breast cancer biology.Cancer Biomark. 2013;13(3):161-9. doi: 10.3233/CBM-130347. Cancer Biomark. 2013. PMID: 23912488 Review.
-
Beta blockers and breast cancer mortality: a population- based study.J Clin Oncol. 2011 Jul 1;29(19):2635-44. doi: 10.1200/JCO.2010.33.5422. Epub 2011 May 31. J Clin Oncol. 2011. PMID: 21632503
-
[β-blockers: a new and emerging treatment for melanoma].Recenti Prog Med. 2012 Jan;103(1):11-6. doi: 10.1701/1022.11152. Recenti Prog Med. 2012. PMID: 22322621 Italian.
-
Can all beta blockers improve the breast cancer survival?Breast. 2012 Feb;21(1):107-8. doi: 10.1016/j.breast.2011.09.015. Epub 2011 Oct 17. Breast. 2012. PMID: 22001140 No abstract available.
-
β-Adrenergic Receptors : New Target in Breast Cancer.Asian Pac J Cancer Prev. 2015;16(18):8031-9. doi: 10.7314/apjcp.2015.16.18.8031. Asian Pac J Cancer Prev. 2015. PMID: 26745035 Review.
Cited by
-
The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.Cancer Chemother Pharmacol. 2023 Dec;92(6):485-499. doi: 10.1007/s00280-023-04586-9. Epub 2023 Sep 19. Cancer Chemother Pharmacol. 2023. PMID: 37725114
-
Differential β₂-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines.Oncotarget. 2014 Oct 30;5(20):10058-69. doi: 10.18632/oncotarget.2460. Oncotarget. 2014. PMID: 25375203 Free PMC article.
-
Neurotransmitters: emerging targets in cancer.Oncogene. 2020 Jan;39(3):503-515. doi: 10.1038/s41388-019-1006-0. Epub 2019 Sep 16. Oncogene. 2020. PMID: 31527667 Review.
-
β2-Adrenergic Signalling Promotes Cell Migration by Upregulating Expression of the Metastasis-Associated Molecule LYPD3.Biology (Basel). 2020 Feb 22;9(2):39. doi: 10.3390/biology9020039. Biology (Basel). 2020. PMID: 32098331 Free PMC article.
-
Pharmacological blockade of a β(2)AR-β-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model.Cell Cycle. 2013 Jan 15;12(2):219-24. doi: 10.4161/cc.23368. Epub 2012 Jan 15. Cell Cycle. 2013. PMID: 23287463 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical